Penumbra CEO Urges Shareholders to Vote FOR Boston Scientific Merger Ahead of May 6 Special Meeting

**TL;DR** Penumbra's CEO, Adam Elsesser, urges shareholders to approve the proposed merger with Boston Scientific at the upcoming May 6 special meeting. The company's board unanimously recommends a "FOR" vote, emphasizing that abstaining counts as a vote against the deal.

Penumbra shareholders confront a pivotal decision regarding the company's proposed merger with Boston Scientific, with a special meeting set for May 6, 2026. This significant transaction aims to unite two key players in the medical technology sector, potentially reshaping market dynamics. The resolution of this meeting will define Penumbra's strategic path forward.

The Board of Directors for Penumbra has unanimously advised shareholders to vote in favor of the merger. This consensus among the board members signals a strong belief in the strategic advantages and long-term value that the proposed combination could deliver. CEO Adam Elsesser recently reaffirmed this recommendation in a direct letter to stockholders.

Elsesser's communication stressed the necessity for every shareholder to actively participate in the voting process. He particularly highlighted a crucial procedural aspect for the May 6 meeting: any vote not cast will automatically be recorded as a vote against the merger. This policy means inaction carries the same weight as an explicit rejection, underscoring the importance of submitting a definitive ballot.

Shareholders received proxy materials detailing the merger proposal and voting instructions in advance of the meeting. These documents outlined the reasons for the board's recommendation and provided methods for casting votes, including by telephone, internet, or mail. The board's consistent support reflects their assessment of the merger as a beneficial step for the company.

The outcome of this shareholder vote will directly influence Penumbra's future market position and operational strategy. An approval would pave the way for integration with Boston Scientific, while a rejection would necessitate a re-evaluation of Penumbra's standalone trajectory. The medical technology sector will observe the results closely.

All eyes will turn to the special shareholder meeting on May 6, 2026, as investors await the final decision on this significant industry consolidation.